<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04961385</url>
  </required_header>
  <id_info>
    <org_study_id>111/64</org_study_id>
    <nct_id>NCT04961385</nct_id>
  </id_info>
  <brief_title>Immunogenicity of the ChAdox1 n CoV-19 Vaccine With 12-dose Vial</brief_title>
  <official_title>Immunogenicity of the ChAdox1 n CoV-19 Vaccine Against SARS-CoV-2 With 12-dose Vials: an Interim Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bangkok Metropolitan Administration Medical College and Vajira Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bangkok Metropolitan Administration Medical College and Vajira Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ChAd0x1 nCoV-19 (AZD 1222) is the main vaccine that is planned to roll-out in Thailand and&#xD;
      involve vaccinating people especially in high-risk categories. This vaccine is contained in&#xD;
      the multiple-dose vial for vaccinating 10 recipients for 0.5 mL each. However, the additional&#xD;
      volume of vaccine was overfilled to 6.5 mL per vial which the vaccination can be administered&#xD;
      to more than 10 doses. The University Hospital Network (UHOSNET) and Faculty of Medicine&#xD;
      Vajira Hospital, Navamindradhiraj University have jointly stipulated the preparation and&#xD;
      vaccination of ChAdox1 - n CoV-19 vaccine with 12 doses per vial injection with traditional&#xD;
      21 or 24 G needle. Taken together, The investigators planned to investigate the immune&#xD;
      response of participants after first dose of ChAd0x1 nCoV-19 vaccination with such technique&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators measured anti-SARS-CoV-2 antispike RBD IgG and neutralizing antibody by&#xD;
      surrogate virus neutralizing test (sVNT) in adults between age 18-72 year after first dose of&#xD;
      ChAd0x1 nCoV-19 vaccine.The primary outcome was the antibody levels.The secondary outcome&#xD;
      were adverse events,factors affecting antibody levels and incidence of COVID-19 infection at&#xD;
      the time of study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Actual">May 31, 2021</completion_date>
  <primary_completion_date type="Actual">May 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Antispike RBD IgG level</measure>
    <time_frame>Baseline</time_frame>
    <description>Level inBAU/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antispike RBD IgG level</measure>
    <time_frame>3 monnths</time_frame>
    <description>Level inBAU/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antispike RBD IgG level</measure>
    <time_frame>6 months</time_frame>
    <description>Level inBAU/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibody</measure>
    <time_frame>Baseline</time_frame>
    <description>Percent inhibition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibody</measure>
    <time_frame>3 months</time_frame>
    <description>Percent inhibition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibody</measure>
    <time_frame>6 months</time_frame>
    <description>Percent inhibition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>through study completion,an average of 1 year</time_frame>
    <description>Any abnormal symptoms post vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Covid-19 infection</measure>
    <time_frame>through study completion,an average of 1 year</time_frame>
    <description>Incidence of COVID-19 infection</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Covid19</condition>
  <condition>Vaccine</condition>
  <condition>Immunogenicity</condition>
  <arm_group>
    <arm_group_label>ChAd0x1 nCoV-19 vaccinees</arm_group_label>
    <description>Participants who received first dose of ChAdox-1 n COV-19 were recruited. Participants were eligible if they were more than 18 years old</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunogenicity after first dose of participants who received first dose of ChAdox-1 n COV-19 vaccine</intervention_name>
    <description>Blood samples were taken from the vaccinated participants for antibody testing against SARS-CoV-2</description>
    <arm_group_label>ChAd0x1 nCoV-19 vaccinees</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who received first dose of ChAdox-1 n COV-19 were recruited.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants were eligible if they were more than 18 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergic to components of vaccine&#xD;
&#xD;
          -  Risk of COVID-19 infection in the previous 14 days before enrollment i.e close contact&#xD;
             with index cases or history of fever with upper respiratory tract infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Thananda Trakarnvanich</name>
      <address>
        <city>Bangkok</city>
        <zip>10300</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Le Dar√© B, Bacle A, Lhermitte R, Lesourd F, Lurton Y. Maximizing number of doses drawn from multi-dose COVID-19 vaccines by minimizing dead-volume. J Travel Med. 2021 Jun 1;28(4). pii: taab049. doi: 10.1093/jtm/taab049.</citation>
    <PMID>33772277</PMID>
  </reference>
  <reference>
    <citation>Kesten JM, Ayres R, Neale J, Clark J, Vickerman P, Hickman M, Redwood S. Acceptability of low dead space syringes and implications for their introduction: A qualitative study in the West of England. Int J Drug Policy. 2017 Jan;39:99-108. doi: 10.1016/j.drugpo.2016.09.005. Epub 2016 Oct 24.</citation>
    <PMID>27788406</PMID>
  </reference>
  <reference>
    <citation>Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, Hu Z, Chen VC, Young BE, Sia WR, Tan YJ, Foo R, Yi Y, Lye DC, Anderson DE, Wang LF. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020 Sep;38(9):1073-1078. doi: 10.1038/s41587-020-0631-z. Epub 2020 Jul 23.</citation>
    <PMID>32704169</PMID>
  </reference>
  <results_reference>
    <citation>Strauss K, van Zundert A, Frid A, Costigliola V. Pandemic influenza preparedness: the critical role of the syringe. Vaccine. 2006 May 29;24(22):4874-82. Epub 2006 Mar 20.</citation>
    <PMID>16647790</PMID>
  </results_reference>
  <results_reference>
    <citation>Mehran R, Dangas GD, Weisbord SD. Contrast-Associated Acute Kidney Injury. N Engl J Med. 2019 May 30;380(22):2146-2155. doi: 10.1056/NEJMra1805256. Review.</citation>
    <PMID>31141635</PMID>
  </results_reference>
  <results_reference>
    <citation>Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20. Erratum in: Lancet. 2020 Aug 15;396(10249):466. Erratum in: Lancet. 2020 Dec 12;396(10266):1884.</citation>
    <PMID>32702298</PMID>
  </results_reference>
  <results_reference>
    <citation>Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, T√∂r√∂k ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Erratum in: Lancet. 2021 Jan 9;397(10269):98.</citation>
    <PMID>33306989</PMID>
  </results_reference>
  <results_reference>
    <citation>Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M, Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ, Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG, Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC, Snape MD, Song R, Tarrant R, Themistocleous Y, Thomas KM, Villafana TL, Warren SC, Watson MEE, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Faust SN, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19. Erratum in: Lancet. 2021 Dec 19;396(10267):1978. Lancet. 2021 Apr 10;397(10282):1350.</citation>
    <PMID>33220855</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 25, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bangkok Metropolitan Administration Medical College and Vajira Hospital</investigator_affiliation>
    <investigator_full_name>Thananda Trakarnvanich</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Neutralising antibody</keyword>
  <keyword>Antispike RBD</keyword>
  <keyword>ChAd0x1 nCoV-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Mandeley website</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>As soon as the manuscript is accepted for publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

